curcumin and Lupus-Nephritis

Curcumin is the active ingredient in the curry spice turmeric. It has anti-inflammatory properties due to the inhibition of transcription factors and inflammatory mediators such as nuclear factor-. A search was conducted following guidelines in the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) using the PubMed, Google Scholar, Scopus, and MEDLINE electronic databases to retrieve relevant studies assessing the impact of curcumin supplementation on SLE.. Despite the wide use of curcumin in everyday life, its molecular and anti-inflammatory use has only been partially explored. Current data show a potential benefit on disease activity. Still, no uniform dose can be advised because long-duration, large-scale randomized trials using defined dosing are needed in different subsets of SLE, including lupus nephritis patients.

Topics: Animals; Anti-Inflammatory Agents; Curcumin; Dietary Supplements; Humans; Interleukin-6; Lupus Erythematosus, Systemic; Lupus Nephritis; Mice; Proteinuria; Randomized Controlled Trials as Topic

Over recent decades, many clinical trials on curcumin supplementation have been conducted on various autoimmune diseases including osteoarthritis, type 2 diabetes, and ulcerative colitis patients. This review attempts to summarize the highlights from these clinical trials. The efficacy of curcumin either alone or in conjunction with existing treatment was evaluated. Sixteen clinical trials have been conducted in osteoarthritis, 14 of which yielded significant improvements in multiple disease parameters. Eight trials have been conducted in type 2 diabetes, all yielding significant improvement in clinical or laboratory outcomes. Three trials were in ulcerative colitis, two of which yielded significant improvement in at least one clinical outcome. Additionally, two clinical trials on rheumatoid arthritis, one clinical trial on lupus nephritis, and two clinical trials on multiple sclerosis resulted in inconclusive results. Longer duration, larger cohort size, and multiple dosage arm trials are warranted to establish the long term benefits of curcumin supplementation. Multiple mechanisms of action of curcumin on these diseases have been researched, including the modulation of the eicosanoid pathway towards a more anti-inflammatory pathway, and the modulation of serum lipid levels towards a favorable profile. Overall, curcumin supplementation emerges as an effective therapeutic agent with minimal-to-no side effects, which can be added in conjunction to current standard of care.

Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Autoimmune Diseases; Colitis, Ulcerative; Curcumin; Diabetes Mellitus, Type 2; Humans; Lupus Nephritis; Multiple Sclerosis; Osteoarthritis; Randomized Controlled Trials as Topic; Rheumatic Diseases; Treatment Outcome

Despite highly expensive treatments, lupus nephritis remains a major cause of morbidity and mortality in patients with relapsing or refractory lupus nephritis. Meanwhile, experimental studies indicate that curcumin attenuates both the binding of autoantibodies from systemic lupus erythematosus patients to their cognate antigens and also the inflammatory responses of tumor necrosis factor-alpha-stimulated human endothelial cells. Therefore, in this study we investigated effect(s) of oral curcumin supplementation on patients suffering from relapsing or refractory lupus nephritis.. A randomized and placebo-controlled study was carried out.. The present study was conducted in Lupus clinic of Hafez Hospital, Out-Patient Department of Shiraz University of Medical Sciences.. A total of 24 patients with relapsing or refractory biopsy-proven lupus nephritis, who were randomized in 2 groups (trial [n = 12] and control [n = 12] groups) were included in this study.. With each meal, each patient in the trial group received 1 capsule for 3 months, which contained 500 mg turmeric, of which 22.1 mg was the active ingredient curcumin (3 capsules daily). The control group received 3 capsules (1 with each meal) for the same period, which contained starch and were identical in color and size to capsules given to patients in the trial group. MAIN AUTOMATIC MEASURE: Data were analyzed using Statistical Package for the Social Sciences software version 15.0.. A significant decrease in proteinuria was found when comparing pre- (954.2 ± 836.6) and 1, 2, and 3 months supplementation values (448.8 ± 633.5, 235.9 ± 290.1, and 260.9 ± 106.2, respectively) in the trial group. Also, systolic blood pressure and hematuria were found to decrease significantly when pre- and post-turmeric supplementation values were compared in the trial group. However, placebo capsules did not exert any statistically significant effect on measured variables in the control group over 3 months of the study. No adverse effect related to turmeric supplementation was observed during the trial.. Short-term turmeric supplementation can decrease proteinuria, hematuria, and systolic blood pressure in patients suffering from relapsing or refractory lupus nephritis and can be used as an adjuvant safe therapy for such patients.

Topics: Adult; Curcuma; Curcumin; Dietary Supplements; Female; Hematuria; Humans; Hypertension; Lupus Nephritis; Male; Phytotherapy; Placebos; Proteinuria; Recurrence

Curcumin is known to have immunomodulatory potential in addition to anti-oxidant, anti-inflammatory and anti-carcinogenic effects. The aim of the present study is to investigate the therapeutic effects of curcumin on immune-mediated renal disease in an anti-glomerular basement membrane (GBM) model (representing acute kidney Injury, AKI) and murine lupus model (representing chronic kidney disease, CKD). In the AKI model, female anti-GBM 129/svj mice were administered with curcumin right before disease induction. In the CKD model, female MRL.

Topics: Animals; Anti-Inflammatory Agents; Autoantibodies; Autoimmune Diseases; Basement Membrane; Curcumin; Disease Models, Animal; Female; Glomerulonephritis; Kidney; Kidney Glomerulus; Lupus Nephritis; Mice; Mice, Inbred MRL lpr; Proteinuria; Signal Transduction; Spleen; Splenomegaly

Despite rapid progress in the understanding of systemic lupus erythematosus (SLE), there is still an urgent need for novel and more effective interventions. Curcumin, a natural polyphenol compound, has been shown to be anti-inflammatory in various disorders. In this study, we investigated the potential therapeutic value of curcumin in SLE. Lupus-prone female MRL/lpr mice were treated with curcumin. The development and extent of nephritis were assessed by monitoring proteinuria and by histologic analysis. Serum anti-dsDNA levels were measured by enzyme-linked immunosorbent assay. Kidney samples were analyzed by Western blot. In vitro, mouse podocytes were used for investigation in the presence of mouse anti-dsDNA antibody-positive (anti-dsDNA+) serum. Curcumin treatment dramatically decreased proteinuria and renal inflammation. Serum anti-dsDNA levels and spleen size were also reduced by curcumin. In addition, curcumin reduced NLRP3 inflammasome activation in lupus-prone mice. In vitro, curcumin significantly inhibited anti-dsDNA+ serum induced expression of NLRP3 inflammasome in podocytes. Overall, these data demonstrate the potential use of curcumin in SLE treatment.

Topics: Animals; Anti-Inflammatory Agents; Antibodies, Antinuclear; Cells, Cultured; Curcumin; Disease Models, Animal; Female; Humans; Inflammasomes; Kidney; Lupus Erythematosus, Systemic; Lupus Nephritis; Mice; Mice, Inbred MRL lpr; NLR Family, Pyrin Domain-Containing 3 Protein; Podocytes; Proteinuria

Curcumin has been used in Asian traditional medicine for its medicinal properties. Recent studies have demonstrated that curcumin has antioxidant, anti-tumour and anti-inflammatory activities. The aim of the present study is to investigate the effects of curcumin on established lupus nephritis (LN) in New Zealand Black/White (NZB/W) F1 female mice, in particular, its interaction with regulatory T (Treg) cells. Starting at 18 weeks of age, mice were fed a standard diet or a diet containing 1 % curcumin until the end of the study. The proteinuria level and the serum levels of IgG1, IgG2a and anti-double-stranded DNA (dsDNA) IgG antibodies were measured. Additionally, IgG immune complex deposition in the glomeruli and renal inflammation were compared between curcumin-treated mice and control mice. Curcumin decreased the proteinuria level and serum levels of IgG1, IgG2a and anti-dsDNA IgG antibodies in NZB/W F1 female mice. IgG immune complex deposition in the glomeruli was reduced in curcumin-treated mice. Furthermore, renal inflammation was also decreased after curcumin treatment. Interestingly, these therapeutic effects of curcumin disappeared after Treg depletion by anti-CD25 antibody injection. Curcumin exerted a protective effect against LN in NZB/W F1 mice. We speculate that the protective effects of curcumin in LN may involve, at least in part, its interaction with Treg cells.

Topics: Animals; Antibodies; Antibodies, Antinuclear; Antigen-Antibody Complex; Curcuma; Curcumin; Dietary Supplements; Female; Immunoglobulin G; Interleukin-2 Receptor alpha Subunit; Kidney Glomerulus; Lupus Nephritis; Mice; Mice, Inbred NZB; Phytotherapy; Plant Extracts; Proteinuria; T-Lymphocytes, Regulatory